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When iuitisiea a few days after myocardial infarction, angio- 
tensin-converting~ enzyme inhibition exerts beneMo! effetts on 
5urvivd and tiorb&Wy in @tie& with asymptomatic left veatric- 
uiar sys#olir dysfmnction or sympiomatic he&t faihm. Duiiag the 
acute phase of a mymardiai infarctios atngiotensic-coaverting 
enzyme iahibitim appks to be well tolerated, to pevent the 
.deveiopwnt of beart failure in patients with asym@matic left 
reatricvlar systolic dy&anction ;a~! to improve the hymodynamic 
Over the past. 15 years, angiotensinx.onverting enzyme inhib- 
itors ham been found ,to be increasingly, beneficial in patients 
with chronic congestive heart failure (I). Initially, angioknsin- 
converrmg enzyme. iahibitors were’evaluated in patients with 
Fevere symptoms 6f congestive heart failure who were in New 
York Heart &sociation functional class, IIl,or .IV (23 Later, 
angiotensin-converting enzyme inhibition was collsidered for 
pqtients with mikler symptoms compatible with functional class 
I or II and,,more recently. for patients with asymptomatic left 
ventricular qstolic dysfunction (4-6), Although the preven- 
tion arm of the Studies of Left VentriCufar Dysfunction 
(SOLVD) trial (5) failed tc shoiv a benefit, of Iqng-term 
administration of enatapril on mortality, morbidity, in terms of 
development of ;coligestive heart failure or hdspiral admissitin 
for congestive heap’ f+lurk, ,was Substa:tialfy reduced, in 
paatients receiving krralapril cbmpa+d with. thrise receiving 
placebo. 
While the in&z..t_ons for. an$otensin-converting enzyme 
infiibition in patients ’ ,,ith chronic : l@ ventrictilar systolic, 
dysfunction with or without congestive heart failure were 
widening, the role of angiotensin-converting~enzyme inhibifion 
was being e,valuatcd in patients,with recent acute myckardial 
infar&on (7). Because cc*rlgestivk heart failure in North 
America &most c&e; related ro tironq artery diskse, acute 
,myocardial ir‘&crioq and the tesulting left ve!liricular systtilic 
dysfucct%rr.~ztr~ a cirar theiapeuric target if cue has it-i@ mind 
; ..I ; :, 
and clikal variables of heart failure when present. Accwdingly 
early angiatensin-cmverting enzyme. inhibition is clearly.: indi: 
eated in patients v4th acute mjacardial inLrc& associati with 
asya3pt~matk left vretricuutar dysfuactioir~or flitcal evideace of 
heart failure. Angioteusinxoovertiag me inhrlitioo may also 
be ben&cial when tkornbolytk agents bil to -restore au-onary 
patency in patients wirh acute myocardial iofarcticn. 
(J Am Cdl tkc5.d k 99~25[Suphenrj:47~51S) 
to significantly alter the ilaturai history of congkst+e heart 
failure (8). 
Large Raa&mized Stidies of 
Aq$stensJnlCouverti~g Enzyme In hibi tars im 
Patients Wirth Acute Mjwardiai InParctitin 
In 2,231 patients with a left ventricular ejectioe fraction 
~40% and without noticeable symptoms of congestive heart 
failure, the Survival and ~eI’IEriCUk!r Enlargement (SAyEj 
‘trial (9) clearly demonstrateh the benefits of long-tee sdmin- 
istraiion if raptopril on overall mortali,~ and’ prev&$ion @f.. 
‘spp~o.m$ic congeWF h+rt failure and,Futiefit ,tiyctcardial 
‘infarction over’ that obser& in patients rtiivi& @lacebo 
(Table 1). Administration of captbprti or pIaceb0 was initiated 
on. average 11 days after the acute event, once the eventual 
need for mronaq angioplassty or byjxq s&q had be& 
axseS;sed and performed if oeedea. In ,that regw, &a from 
the SAVE trial -are pertinent E? &$mptomak pa&B in’ the 
convalescent .phw, of an xute pyocardial ‘i&r&xl tid. do 
not help to ‘define .the indicatiotis for immediate angiotekin- 
converting &@-@ mhibitik &patients with evoking :@y&&- 
diai infar&on.‘Of Mite, the. beneiit‘ of ‘c;lptop$ on. moality 
bekukappare~~ only after !2 ~oi~li;s aad WS, l@hly Signifi- 
‘cant after. ari sverage f@@+up per&;; of 42’months. ’ 
A double-b6!:d;p~~bo-contro!ted trial &sin&a sk.,$, 
that b;f SAVE recently repartrd (10) the benefits of angiotcn- 
sin-con~@ttig~ eqzyqe irhbitiim ui;,th rkm@ril qn. mprtality 
!l .and mqrbidity i6 p~~ents~i~h~3ctlte.my~ardial~Hifarction kd 
~.:ar&ert~ evid&e of’ h&t f&lure.. The &Me Infarction 
-.: ., .’ .’ 
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SAVE Pi. &I’ 11 d post-MI,’ no isch- :- Cal~to&l 42 mo 19% 22% ” 
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EF ~40% ” 
3 d post-M5 clinical Ramipril 15 mo 27% 19% ” Nk 
or i&o@kpliic 
: hcati failure 
SMlLE (! 1) l.SIib 1st 24 h of ant MI: Zofenupril iiwk NS 49% NS 
SBP > I00 mm Hg 
GfSsI-3 (12) ‘,I934 lst.24 h, al; comers Lisiliopril 6wk 11% N#? NA, 
cGNsENsus II (15) film 1st 24 h; all comers Enalapriiat 6mo ‘, NS 29% NS 
‘Numbers i parentheses are reference numbers. ACE = augiotensin-canverting enzyme; AIRE = Acute Infarction Ramipril Efficacy trial; ant = anterior; CHF = 
rmrgestive ha failure; CONSENSUS 11 = Cooperative New Scandinaviiut,En;;lapril ‘Survival Study; d = days; EF = cjeciion fraction; GISSI-3 = Gruppo ltaliano 
per lo,Studia’della Soprawivenza netl’tnfarto Miocardico; MI = myocardial infarction; NA = not applicable; Pts = patients; SAVE = Smvival and Ventricular 
Enlargement trial; SBP = systolic blood p&ure; SMILE = Survival of Mytirdial Infarction Long-Term Evaluation trial. 
timiprii Eticacy @IF&E) study investigators found that 
ramipril ,reducql overalI’,mo@ity by 27% a-ld resistant con- 
gestive heart fail- by 1% compared -with placebo. Of 
interest, the benefit of ramipril,on mortality became apparent 
.as early as 30 .days after-the acute eveni and was L@ly 
significant after 15 months.of foljow-up. 
Ad&&ration of ramidril er placebo was,initiated from 3 
to 10 days after the ac~lte event. Thus, as noted with the SAVE 
t&J, data from the AIRE study are pertinent :o the convales- 
c&t phase’of myocardial i&rction for patients who, at one 
,pointi had clinical or, radio&raphic evident of heart failure. 
hilOre ‘recently, the effects of early angiotensin-converting 
empie in&iitiori with zofenopril on thi prevention of severe 
cungkstive heart f&lure were evaluated in l>SB patients with 
an a&e anterior wa myo~rdial infarction-by the Survival of 
Myadd, Infarction Long-Term EVal~tion .trial (SMILE) 
investi$&ors .(ll).“ &dministraiioi and dose titration of the 
study drug were:, @xx with great care to, avoid syitemic 
hypoteosion, that &,systotic blood praure <lo0 mm Hg. 
During the 6 weeks, of doubie-btind treatment. 34 patients 
(4.3%) dcvcloped se!ere congestive heart ‘failure in the -p!a- 
@IO gyqi, yxd 17 patients (Q%)’ did SO in .the zofenopril 
g.mup, wiih a risk reduction of- 49% (95% co@dence interval 
[CI] 11% to 171%, p * O-018). En agreement with the findings 
of fhe SAVE investjgapr? $t+r .42 months “I$ the AIRE: 
investigators after.-lS months, the OVI@ morttahiy tended to 
he de&eased in patients in th+ zofenopti grouti compared witti 
that m ” the -placebo : group, that is, SO Verse 60 de$hs, 
respectively, with a risk reduction of 22%‘,(9$% CI - 12% to 
-48%; p = Q:i7i).,,Administra@on of z.ofenopril or &&o 
was started wit&in the first 24 h of onset :of acute m*car&al 
i&u-&ion. Although the incidence ‘of systolic. blood pressure 
<lOO mm i-Ig was greater iii the zafenopril ‘pup, the’ Fate of 
’ discix&m&~~ of the study drug because of si&iflcant hypo- 
: ten&n was not imxeased in the zofen&pri) grpup comptied. 
with that fur the placebo group (3.8% vs, 27%,: p. = NS). 
In the Gruppo Italian0 per IO Studio deIia Soprawivenza 
nell’lnfarto Miocardico (tiISSl-3) trial .(12:, patients &th 
acute myocardial infakc:ion in K&p class 1. or 2 who were 
treated within 24 h of symptoms with lisinopril had a tower 
mortality rate at 6 tieeks than those t;-eatcd with placebo (6.3% 
vs. 7.1%, p = 0.03). Of interest, these findings were observed 
iti a population. intensively eiposed to’ reammended treat- 
me& including throtibolysis, b&a-blockade and a$&. 
Finally, preliminary results from the Collaborative Group 
Fourth international Study of Infarct survival (ISIS-4) (13,14) 
also indicate a lower mort&y rate at 35 days in patients 
with acute myocardial infarction treated with captopri1 than 
that noted in pat:ents receiving place!& (7.1% vs. 7.6%, p < 
0.02). 
In contrast to the resuits of the FAVE, AIRE, SMILE, 
GESSI3 a&ISIS-4 &ids, the re+hs: @he Cooperative N+.w 
ScandinaLian Enaiapril Study ;(CON&N§& II) (15) &er& 
negative. The CONSENSUS II trial failed to demonstrate any 
benefit of enatapril therapy initiated within the &st 24 h of 
acute myocardial inf&ti& c?mp&d with placebo. Adtiinis- 
tration of enalapril-or pIacebo was’iriitiated early in the c&n-se 
of, myocardial infaiction, ,first by- parenteral form and. $ubsr;- 
quently by the oral route. The.Safety Committee, which had 
concerns about the. possible’ adverse effects of ehal+l in 
elderly p+i&ts with .zatly hypot@ion; decided, to-interrupt 
the trial after a B-month fojl&v-up, which” in view’ of the;. 
:elative& small number of j$ati&s en&led ,compared with 
megatr;ials, may, have been too short to d&ect a re&tion in 
m&t&$ wifh enalafirii in .a11 patients :with acute rnjlocea;, 
dial ‘i@rctioti; Surprisingly; the &bgrou$ aridysis,,of +ei 
CONSEN$B 11 findings ,did not- document any, b&&t of 
enalapril in th& Subset ‘of j~atie@s with -a: historj of rx>ngest&e 
heart failure, puh&naryedema 0;‘. h* failure af@r ‘ad& 
siun. These subsets of patients we+-quite,smail @%, 2% and 
13%; resptitive~),- : -F 
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‘. .. : Positii;re Studies’ (SAVE, AIR& S@@LE, 
4qSP-3, ~Jsrs’g) VePsus Negatiw? 
‘p~~&.~es we-e similar to thqse noted by MC&pine ct al. (J5): 
: 18 to 10 mfq Hg and 4 to 6:mm I-& respectively. 
.’ ; .,;- Studies (CONS~SU$ II),- In a rahdomized stlidy of captopril. .versus placebq in 
$‘lie~~.c~~tr~s~ing findings -‘betw~eli the SAVE, AIRE, 
patients with acute myoc+r&aI irifatition treat&d with intra$e-, 
.SMILE;. t3!SSI+ and I$++ trials on: the one hand and the 
n@~s I nitroglyc&rin, Tranchesi ef & (18) demonstiated that 
CO~S~l@US TI Gal .zi thi= other’ pr@b&ly result from 
cOnc&nitllnt administtition 6f captopril and nitro&ceti &as: 
niultiplq factqrs. The ~patiec~ r,@ulation ivas most Iikely the 
’ de in ihc early hours of a ntin~mplicated anterior wali, 
most influential factor to Txpiain :5c @&renc~s-in outcome 
myocardial infarction. However. &ty patients w&h a mean 
between the SMILE and CONSENSUS II trials. Patients 
s$temlc arterial pressure .>70 mm Hg. cardiac index, >2.2 
enrolled in the SMILE were more likely to develop left 
Iiters/miri per II? and pulmonary capillary wedge pressure 
vent.ficular dysfunctitin and heart failure because of the ante- 
>lO mm Hg were included in the trial. Finally, in a randcm- 
rior wall location of.tiyocar&al d&nag&than those enrolled in 
ized, placebo++rolled trial involving 38 patients with acute 
the CONSENSUS II trial, although the timing of study drug 
myoca~dial’infarct~n, Nabel.et al. (19) reported that simulta- 
adminstration was similar ih both trials, that is, the first 24 h. 
neous administration, of intravenous captopril and recombi- 
Although thz CONSENSUS II, GISSI-3 and ISIS-4 trials are 
nant tissue-type plasminugen activator did not lead to tiny 
similar with regard t6 Lhe early administration of angotensin- 
hemodynamic complicaticjns. However, intravenous adminis- 
converting enzyme inhibition,during the course oi the myocar- 
tration of ca$opril had to be discontinued in only one patient. 
dial infarction, these studies,differ on the number of patients 
Of note, three patients in th? captopril group underwent 
enrolled, which is at least threefold greater in the GI$SI-3 and 
coronary bypass surgery before d;%zharge, but none did in iit;-- 
ISIS-4 trials than in CONSENSUS II. The major digerence 
placebo g&p. 
among the SAVE, AIRE and CONSENSUS II trials is obvi- 
ously the duration of follow-up: a maximum of 42 months Potential Adverse E+cts of Initiating 
versus a minimum of 4 months. in addition, therapy wi:h 
captopril or ramipril was initiated during the cqnvalescent 
Anqjioteosin-Converting .Enzyme Imhibitioa 
phaz of myocar$ial infarction in the SAVE and:AIRE trials, 
in the First Hours of an Acute 
hut, enalaprilat and’ later enalapril were BdFinistered very Myocardial Iafar@ola 
early during the. &our& of myoca&aI infarction in the .The published data indicate that although it is a&ociated 
CONSENSUS II trial. l$~, acute hypotension induced by with a decrease in mean systemic &rterial pressure averaging 
angititensinsonverting enzyme inhibition and the r&uiting 10 mm Hg, immediate angiotensin-converting enzyme inhibi- 
risk of exacerbating myokardial ischeniia tiuring an evolving tion is hemodynamically and clinically well tolerated in pa- 
myocardial infarction may have occurred in patients enrolled tients with acute myocardial infarction. The coronary perfusion 
in the CONSENSUS II, but it was less an issue in the pbtients pressure gradient, which is the difference between distal core- 
receiving captopril or ramipril in the SAVE and AiRE trials. nary and left ventricular diastolic pressures, may be preserved 
or even enhanced by angiotensin-converting enzyme inhibition 
in patients with an elevated left venqic+r d@stoIic pressure. 
Acute Hemsdyraank Effecks of 
In these ‘patients, the detrimental effect o{ a decre,ase in:, 
Angiotensiu-C&vertimg ‘knzyme Inhibition 
systemic arterial pressure ori the coronary perfusion gradietit is 
likely to be offset by a co&m&ant reduction in left ventricular 
5~ Acute M$ocar@al Infarction diastolic pressure. in contrast, coronary perfusion pressure 
‘Few investigators have &lied the hemodynanic clkcts of ‘grdiiient may de,crcase in patients with a normal or low left 
early angiote&in-cunv&ng enzyme inhibition in patients with ventricular diastolic pressore. Indeed, besides di:-ectly decreas- 
evolving my&dial infarction .(16-19). M&pine et al. (Zj ‘ing arteriolar resistances, angiotensin-converting enzyme inhi- 
evaluated. nine with an acute :mjrocardial’ infarction and left Uition may precipitate a decrease in’ stroke volume as left 
ventricular failure:tibo were:ttiated &th captrlpril within the ventricular d@+tolic pressures decrease in patie’zl!s whose left 
first:48 h af s$ngtomi. Mean &e&i+ arterial and puI&onq ventricles are *rating bn the steep part of the Sta<ling cirve. 
&pillary wedge pressures decre&ed from 84 to 76 mm i-ig and : Such reduction in coronary perfusion ,pressure gradient may 
from 26 to 20 mm Hg, ~spe&vei)i, al*ough cardiac output did l&ad’ to -or exacerbate my&dial ischemia in; yktients with 
not ctiange. Severe +temic hypotension did not occur; Ray bt critical coronaq obstruction. -. < 
al, (17) ,studied the hemodyn&&ib effects of early captopnl or .’ 
placebo adtini&ati& .in,99 hemtidynamically stable patients ’ ES 
with actite myocardial .icfarctidn. CaptopriI, sqted bet&&n 6 
Im~icatj@ns far &My Pnitiatjon of ” 
@ti 24 ‘h after- the ai&& &Vent, was not a$sociat& with 
&tgio&sim+mve@ng- ,&ay+Inhit@on 
sig@icant hypotension ‘in patients whose has&tie pulmonajr ” ‘in AcUe Mjo&dial InfwctS~~ : ; . capdlary wedge.pres&re averaged 16 r&-.H& The r+ductior& ‘. The p&e& ‘of “signs and sym$?gs of’ left ventri&u _: 
ir; tie+ &ten&z @&id hd pulmonary capillary Wedge systolic dystinction is clearly an i&port@ deierminant, of the 
early ‘us:’ of: *gio+Gkc.otiv~rting -CrrzjFmr: inhitiition ,iii pa- 
tient? WIF ric:rte.myowd~~‘inf~on. Ititkdiate angiotensin- 
conmdng eiqrne inhibition is’ the pharmacologic interven- 
tion c$ ch~ti in ptknts .v&Cdevelop cli@cal heart failure in 
the e+rIj hours of ~;n acute mjqkii~l kifarction. T@ alter- 
native approkh, ~adm%NSkation bf potent, loop diuretic dkgs, 
has i,hi: ‘disadvantage :of further activating the tienin- 
an$otensit@dosterone bystem and thereby ipqz$ng cardiac 
after&d and paradoxkally @ornoting sodium retention once 
the short-lived effects have diskpated (2@21). Potent loop 
diuretic’ drugs can also result in substantial intravascular 
depletion in $atients chroni@y treated, with diuietic drugs 
who, during-the c&xi of a tiyocardial infarction, cannot 
ingest fluids betiause of nausea and vomit@. Of note. emer- 
gency room administration of excessive doses of loop diuretic 
drugs can lead to intravascular depletion in patients with acute 
myocardial, infarction who were euvolemic before their acute 
coronary occlusion. In turn; intravascular depletion and stim- 
kIation bf, the renin-arigiotensin-d!dosterone system subitan- 
tiaIIy increase the ?keIihood of s$nptor&tic hypotension when 
angiotensin-cokerting enzyme inhibition is initiated shortly 
after Itip diuretic therapy. Thus, in patients who are moder- 
ately symptomatic with acute ,left .ventricuIar dysfunction, oral 
adminis$ration of a short-acting angiotensin-converting en- 
zyme inhibitor,at low dose or careful intravenous administra- 
tion of 1 to 2 mg of enalaprilat ‘is the preftirred therapeutic 
approach. Thi use,.of,potent loop diuretic therapy should be 
reserved for patients with acute left ventricular dysfunction 
who are severeIy symptomatic, such as those with pulmonary 
edema, or to patients whose symptoms fail to be relieved by 
angiotensin-converting enzyme inhibition. When angiotensin- 
converting enzyme inhibition at Iow dose is well tolerated, the 
dose qn be progk&vely incieascd at 8-h intervals to full 
angiotensin-converting enzyme inhibition. When systolic arte- 
rial pressure is borderline, ranging from 90 to JO0 mm Hg, or 
when sympttimatic hypoknkioh otitiq ingiotensin-conv;:rting 
enzyme-inhibition should be withheid and then resumed when 
fea$& at a low dose. 
The i?dications for early angiotensin-conv+ing enzyme 
ighibiirion in ‘patients with acute,, mywrdial infarction with 
noTa or inear-normal Ieft ventritilar function aid &tho!lt 
-dir&l evidence. of heart @&fre haite yet ‘ti be defined. 
Multiple fa&rs are psponsible for the progre&ve dilation of 
the left tintricle after an acuk myocardial infarctibn. ,rhe,size 
: and Iwation of -ttie my&dial infwctioti and the pa&& of 
the .ir&rct-related artery are. probably the most important 
factors in patienk with normaI oi’near-normal left ventricular 
e?d-diastoJic dimepsion and kjcction fraction (22). Thus, pa-, 
tients wiih,Itirgk anterio~,~ali:mjlocardial infarcknrj in’whom 
thromboly$is Or ~&&&&~&on,, or b&h, was unsucq&uI or 
no? attempted should be tre&d,Mh angiotensin-converting 
enzyme inhihitokfor at Icast 3 monttis (&5):In view of triej’ 
variability Sextent and, time of th& ~efi’ven~ricular~~emodeling 
process a& myocard,iaI infarction, two-ditiensional echocar-.! 
diogrqthy shouIcI be repeated .A 3 mon&’ and t!$e need foq: 
angiotensinsonverting enzyme. inhibition &odd be Fa&ssedi : 
: ,: i. I 
(26,27)- Ii contrast ‘to patients wi@ a Iarge myocardi@ infar& 
tion- and left. ventr@lar systoI& dysfunqion, :patients with a 
small hyocardial infarction, nqr+al,Ieft iqntricuI& diinension’ ,, I 
and fuk$ok atid a patent infarct-related c&nay artery are 
unlikely to derive substantial lxqtefit froti imnxdiate angjo- 
tensikonveniag enzyme !.nhibition. ‘. 
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